Alembic Pharmaceuticals is gearing up for a substantial launch schedule in the US market for fiscal year 2025, as announced by Managing Director Pranav Amin. The company aims to roll out twenty-five new products in the US generic segment during this period.
Amin emphasized that Alembic Pharma has received establishment inspection reports (EIRs) for all its facilities, indicating no regulatory issues. The company’s revenue for fiscal year 2024 saw a 19% year-over-year increase, reaching ₹6,229 crore, with the US business contributing 28% to the total revenue. The India business, accounting for 35% of the revenue, grew by 7% in the same period.
For fiscal year 2025, Alembic plans to allocate ₹550-₹600 crore towards R&D, focusing on building a robust pipeline of medications for the US market. This includes areas like injectables, ophthalmology, oncology, inhalation, and dermatology. Amin mentioned that capital expenditures will remain minimal for the next two years, as the company prioritizes optimizing its existing plants.
As reported by IIFL Securities, despite being a relatively recent entrant into the US market, the Vadodara-based company, with a history spanning nearly a century, has significantly closed the gap. Alembic has consistently invested between ₹700-₹750 crore annually in R&D to develop US market products. Furthermore, it has spent over ₹1,800 crore on establishing three new USFDA-compliant manufacturing facilities.
